Sign in to view content

Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration

David A. Eichenbaum, MD, FASRS

Video
Published 2018

Related

Defining a 'Strong' and 'Weak' Response to Anti-VEGF Treatment CI-DME: Retrospective Analysis of 3 DRCR Retina Network Clinical Trials
Sharon D. Solomon, MD
Annual Meeting Talks
2023
Comparative Efficacy of Different Anti-VEGF Treatment Regimens in Patients With nAMD: A Network Meta-Analysis
Diana V Do, MD, FASRS
Annual Meeting Talks
2020
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023

Category: AMD-Neovascular

Anti-VEGF

See more